1. Home
  2. ACIW vs CRNX Comparison

ACIW vs CRNX Comparison

Compare ACIW & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACIW

ACI Worldwide Inc.

HOLD

Current Price

$54.64

Market Cap

4.5B

Sector

Technology

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$42.21

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACIW
CRNX
Founded
1975
2008
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
3.9B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
ACIW
CRNX
Price
$54.64
$42.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$62.50
$76.75
AVG Volume (30 Days)
960.8K
1.3M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
13.09
N/A
EPS
0.37
N/A
Revenue
$1,009,780,000.00
$1,039,000.00
Revenue This Year
$9.67
$720.10
Revenue Next Year
$7.41
$184.67
P/E Ratio
$148.46
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.05
$25.83
52 Week High
$54.95
$57.99

Technical Indicators

Market Signals
Indicator
ACIW
CRNX
Relative Strength Index (RSI) 79.63 71.81
Support Level $46.22 $38.68
Resistance Level N/A $44.89
Average True Range (ATR) 1.73 1.71
MACD 0.98 0.74
Stochastic Oscillator 99.44 97.89

Price Performance

Historical Comparison
ACIW
CRNX

About ACIW ACI Worldwide Inc.

ACI Worldwide Inc develops, markets, and installs a portfolio of software products focused on facilitating electronic payments. The firm's products are sold and supported directly and through distribution networks covering three geographic regions - the Americas, EMEA, and Asia Pacific. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but the majority of the revenue is generated in the United States and EMEA regions. The company's operating segment includes Payment Software and Biller. The company generates the majority of its revenue from the Payment Software segment.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: